fr

CARMAT provides an update on the ongoing receivership procedure – suspension of trading

Share post

CARMAT provides an update on the ongoing receivership procedure - suspension of trading

August 13th 2025

Trading of CARMAT shares suspended, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025

 

 

Paris, August 13, 2025 – 6:00 pm CEST    

 

CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “Company” or “CARMAT”), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025.

 

 

Update on the ongoing receivership procedure

 

Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the “Bid”)[1].

 

This Bid will be assessed by the Versailles Economic Court[2] (the “Court”) at a hearing scheduled on August 19, 2025.

 

The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company’s shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term.

 

Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR)

 

Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens.

 

Another press release will be issued by the Company once the outcome of the court hearing is known.

 

In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart.

[1] « Offre de reprise en plan de cession » (in French).

[2] Tribunal des Activités Economiques de Versailles.

Top of page